EUROFINS DISCOVERX PRODUCTS, LLC

Eurofins DiscoverX Products, LLC specializes in the development and delivery of advanced life sciences research tools and assay technologies for biomedical discovery. Their core capabilities center on high-throughput screening platforms, cell-based assays, and molecular pharmacology solutions that enable drug discovery and target validation. The company provides proprietary reagents, engineered cell lines, and automated detection systems used in academic, pharmaceutical, and government-funded research environments. Technical expertise includes GPCR and kinase target profiling, reporter gene assays, label-free cellular analysis, and functional genomics platforms. Their differentiation lies in the integration of proprietary biosensor technologies and standardized assay protocols that enhance reproducibility and scalability in preclinical research settings. Award history does not provide sufficient detail to identify specific federal agency engagements or recurring contract patterns. As such, no confirmed agency relationships or mission-specific work assignments can be inferred from available data. The primary NAICS code 541380, Scientific Research and Development Services, reflects their role in supporting non-clinical biomedical research through specialized instrumentation and biological reagents. In practice, this positions them as a niche supplier of research-grade tools rather than a direct provider of clinical or operational government services. Their market focus is on enabling discovery-phase science, primarily serving the preclinical research ecosystem rather than public health delivery or operational IT systems. The company is structured as a limited liability entity headquartered in Fremont, California, with no publicly disclosed government certifications. While they operate within the federal research supply chain, their geographic footprint and market presence are primarily anchored in the life sciences innovation corridor of the San Francisco Bay Area, serving a global customer base through commercial channels rather than direct government contracting.